[1] Quartey G, Hallgreen CE, Chan E, Wang N, Lei G, Metcalf M. Benefit-Risk Wave 1 case study report: Telithromycin. London: 2013 2013 24/02/2012. Report No.: 1:b:ii.
[2] Ketek: H-C-354-A22-41: EPAR - Scientific discussion. EMA, 2007 Contract No.: EMEA/H/C/354/A22/41.
[3] Lynd LD, O'Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. Journal of Clinical Epidemiology. 2004;57(8):795-803.
[4] Shaffer ML, Watterberg KL. Joint distribution approaches to simultaneously quantifying benefit and risk. MBMC Medical Research Methodology. 2006;6(48).